文献速递浆细胞疾病

达雷妥尤单抗对自然杀伤细胞的影响及其与复发或难治性多发性骨髓瘤临床结局的关系

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2017-10-24

达雷妥尤单抗是靶向CD38的人源IgG1κ单克隆抗体,在复发和/或难治性多发性骨髓瘤中单药及联合治疗均显示临床活性和可控的安全性。本文评估达雷妥尤单抗单药对NK细胞的药效学影响及NK细胞动态变化对疗效和安全性的影响,汇总GEN501和SIRIUS两项单药研究数据。

要点

  • 达雷妥尤单抗首次给药后外周血总NK细胞和活化NK细胞计数快速下降,治疗期间持续处于低水平,治疗结束后恢复。
  • 达雷妥尤单抗剂量与NK细胞最大减少量之间呈明确的最大效应关系,骨髓中亦观察到类似减少。
  • NK细胞计数减少与达雷妥尤单抗疗效或安全性特征之间无关系,剩余NK细胞仍保留细胞毒功能。

核心结论

  • 达雷妥尤单抗治疗使骨髓瘤患者外周血和骨髓中NK细胞计数快速下降并持续处于低水平,治疗结束后恢复,但NK细胞未被完全耗竭,可能仍参与抗体依赖细胞介导的细胞毒作用(ADCC)、临床疗效和感染控制。
  • NK细胞计数减少与达雷妥尤单抗的疗效或安全性特征之间无关系。

研究设计与样本

  • 体外实验评估达雷妥尤单抗对健康供者外周血单个核细胞(PBMC)中NK细胞计数的影响。
  • 汇总GEN501和SIRIUS两项单药达雷妥尤单抗研究的NK细胞计数、临床疗效和不良事件数据进行评估。

主要发现

  • 达雷妥尤单抗与其他CD38抗体一样,在体外降低健康供者PBMC中的NK细胞计数。
  • 达雷妥尤单抗治疗的骨髓瘤患者首次给药后外周血总NK细胞和活化NK细胞计数快速下降,治疗期间持续处于低水平,治疗结束后恢复。
  • 达雷妥尤单抗剂量与NK细胞最大减少量之间呈明确的最高效应关系,骨髓中观察到类似减少。
  • 达雷妥尤单抗治疗患者来源的PBMC在体外仍能通过ADCC诱导CD38+肿瘤细胞裂解,提示剩余NK细胞保留细胞毒功能。
  • NK细胞计数减少与达雷妥尤单抗的疗效或安全性特征之间无关系。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma. CD38 is expressed at high levels on myeloma cells and, to a lesser extent, on immune effector cells, including natural killer (NK) cells, which are important for daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Here, the pharmacodynamic effects of daratumumab monotherapy on NK cells, and the effect of NK cell dynamics on daratumumab efficacy and safety, were assessed. Daratumumab, like other CD38 antibodies, reduced NK-cell counts in peripheral blood mononuclear cells (PBMCs) of healthy donors in vitro. Data on NK-cell counts, clinical efficacy, and adverse events were pooled from two single-agent daratumumab studies, GEN501 and SIRIUS. In daratumumab-treated myeloma patients, total and activated NK-cell counts reduced rapidly in peripheral blood after the first dose, remained low over the course of treatment, and recovered after treatment ended. There was a clear maximum effect relationship between daratumumab dose and maximum reduction in NK cells. Similar reductions were observed in bone marrow. PBMCs from daratumumab-treated patients induced lysis by ADCC of CD38+ tumor cells in vitro, suggesting that the remaining NK cells retained cytotoxic functionality. There was no relationship between NK-cell count reduction and the efficacy or safety profile of daratumumab. Furthermore, although NK cell numbers are reduced after daratumumab treatment, they are not completely depleted and may still contribute to ADCC, clinical efficacy, and infection control.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017. PMID: 29296857. doi:10.1182/bloodadvances.2017006866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。